Long-term molecular remission in promyelocytic transformation of myeloproliferative disease.
Mollee
P N
PN
Taylor
K M
KM
Williams
B
B
Taylor
D
D
Rodwell
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics / Q000648:ultrastructure*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics / Q000648:ultrastructure*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018450:Disease Progression; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000209:etiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000235:genetics*; D011087:Polycythemia Vera / Q000235:genetics* / Q000473:pathology; D011289:Preleukemia / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D012074:Remission Induction; D013920:Thrombocythemia, Essential / Q000235:genetics* / Q000473:pathology; D019851:Thrombophilia / Q000209:etiology; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D003561:Cytarabine; D014212:Tretinoin; D005047:Etoposide; D015255:Idarubicin; D003630:Daunorubicin